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Background
In May 2007, the Victorian Cancer Oncology Hereditary
Bowel Cancer Group (VCOG HBCG) released a position
statement in regards to the identification of Hereditary
Non-Polyposis Colorectal Cancer (HNPCC) by immuno-
histochemistry (IHC) testing. This was based on the
consensus among clinical groups, that most families
with HNPCC are not being identified and strategies to
improve identification should be implemented. The
VCOG HBCG recommendations was to test all colorec-
tal cancers in patients under 50 years of age by IHC for
MLH1, MSH2, MSH6 and PMS2 proteins, as part of the
routine pathological assessment of cancers presenting in
these patients, without direct consent. This recommen-
dation was supported by the Australian College of
Pathologists and widely circulated to the clinical com-
munity from 2007.
The primary purpose of this audit was to ascertain the
frequency of IHC being performed for consecutive
patients diagnosed with colorectal cancer under 50 years
of age, at three Victorian hospitals since the publication
of the VCOG HBCG position statement. The purpose of
this audit was also to ascertain the number of cases
where IHC results showed loss of expression, which
were referred to the Familial Cancer Centre (FCC) for
further assessment and the outcome of this assessment.
Methods
Lists of patients with colorectal cancer diagnosed under
50 years of age for the calendar years of 2007, 2008,
2009 and 2010 were extracted from each hospital data-
base. Pathology reports for all patients were manually
checked to assess cancer site, stage, mucinous compo-
nent, tumour infiltrating lymphocytes and whether IHC
was performed. Those patients with IHC absent results
were cross-checked with FCC databases to see whether
they were referred for further evaluation and what the
outcome of attendance had been.
Results
Data from three hospitals is presented. 204 patients
were diagnosed with CRC under 50 years of age from
Jan 2007 to Aug 2010. 164 had IHC testing as part of
routine management: 67.5% (27/40) in 2007, 69.8% (44/
63) in 2008, 66.6% (36/54) in 2009 and 72% (36/50) in
2010. One hospital showed a greater increment in rate
of IHC uptake over time. This hospital changed its
synoptic pathology report to include IHC.
Conclusion
There were differences between hospitals in the uptake
of the recommendation to implement routine IHC for
patients diagnosed with colorectal cancer under 50 years
of age. Barriers and enablers were identified for initiat-
ing routine IHC testing at the hospitals. These include
addressing concerns about consent and onus of consent
acquisition if needed, confusion about whether the IHC
testing is a genotype or phenotype test, translation of
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